Claims
- 1. A purified retinoid compound having the structure: ##STR40## wherein the configuration of the C7, C9, and C11 double bond independently is Z or E and the absolute configuration at C13 and C14 is independently R or S; wherein R1 is hydroxyl, alkyl, alkyl halide, alcohol, ester, ether, aldehyde, ketone, carboxylic acid, carboxylic ester, acyl halide, amide, nitrile, or amine; wherein R2 and R3 are independently hydroxyl, halide, alkoxy, ester, alkyl, alcohol, ether, aldehyde, ketone, carboxylic acid, carboxylic ester, nitrile, amine, azide, alkyl halide, acid halide, acid azide, or amide; or wherein R2 and R3, or R1 and R2 may be replaced by a 13,14-oxirane or 14,15-oxirane group, respectively.
- 2. The purified retinoid compound of claim 1, wherein R1, R2 and R3 are hydroxyl groups.
- 3. A pharmaceutical composition which comprises the compound of claim 1 and a pharmaceutically acceptable carrier.
- 4. A pharmaceutical composition which comprises the compound of claim 2 and a pharmaceutically acceptable carrier.
- 5. The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable carrier is a retinol binding protein.
- 6. A compound having the structure: ##STR41##
- 7. A compound having the structure: ##STR42##
Parent Case Info
This application is a continuation-in-part of PCT International Application No. PCT/US92/02904, filed Apr. 9, 1992, which is a continuation-in-part of U.S. Ser. No. 682,909, filed Apr. 9, 1991, now U.S. Pat. No. 5,262,572 the contents of which are hereby incorporated by reference in this disclosure.
Government Interests
The invention described herein was made in the course of work under Grant Numbers CA-49933 and CA-38351 from the National Institutes of Health. The United States Government has certain rights in this invention.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5124083 |
Shealy |
Jun 1992 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
682909 |
Apr 1991 |
|